Pharmaceuticals
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
ROCKVILLE, Md. and SUZHOU, China, Dec. 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-19 08:00
6711
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for its investigational pos...
2023-12-19 05:44
1685
EQT Private Equity to acquire Zeus, a global leader in advanced polymer components used in life-saving medical procedures
* EQT Private Equity to acquire Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies * Transaction highlights EQT's commitment to partnering with leading, purpose-driven companies that deliver inherently critical service...
2023-12-18 23:30
1612
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770
GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announc...
2023-12-18 22:04
2415
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-12-18 20:56
1603
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
10+ Emerging Markets, Japan & ANZ Transition in Final Phase KUALA LUMPUR, Malaysia, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of th...
2023-12-18 20:44
2154
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
2023-12-18 09:49
1611
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
ROCKVILLE, Md. and SUZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-12-18 08:00
6376
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
2023-12-16 15:47
2041
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
2023-12-15 21:00
1678
BioSURE Pro Protective Nasal Spray from the UK: Block airborne viruses instantly for six hours with a Gentle Lavender Scent
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- The weather was gradually cooling down, which means thatHong Kong is entering the winter influenza season. Recently, there has been a significant increase in Mycoplasma pneumoniae infections, the surveillance data from the Centre for Health Protection (CHP...
2023-12-15 20:21
2685
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
2023-12-15 11:14
1884
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
2023-12-15 07:30
1740
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
2023-12-14 21:30
3562
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
2023-12-14 17:00
3879
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
2023-12-14 09:55
2027
The Inaugural Fosun Health Conference on Guangdong-Hong Kong-Macao Healthcare Development Integration Held in Hong Kong to Promote "Three Links" Development
HONG KONG, Dec. 14, 2023 /PRNewswire/ -- The Inaugural Fosun Health Conference onGuangdong-Hong Kong-Macao Healthcare Development Integration was successfully held inHong Kong by Fosun Health on December 12, 2023. With the background of integrating medical services ofGuangdong, Hong Kong and Maca...
2023-12-14 09:00
3908
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
2023-12-14 08:30
1688
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals
2023-12-13 21:00
1621
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces ...
2023-12-13 18:01
2242
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714